MAGE-A3 Double Nickase Plasmid (h): sc-402571-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MAGE-A3 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MAGE-A3 Double Nickase Plasmid (h) and MAGE-A3 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting MAGEA3. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-A3 Double Nickase Plasmid (h) | sc-402571-NIC | 20 µg | $410.00 | |||
MAGE-A3 Double Nickase Plasmid (h2) | sc-402571-NIC-2 | 20 µg | $410.00 |
MAGEA3 encodes MAGE-A3, a cancer-testis antigen normally restricted to germ cells but frequently re-expressed in diverse tumor types, where it can influence cell-state programs linked to proliferation and stress tolerance. MAGE-A3 participates in protein homeostasis by engaging ubiquitin–proteasome-related processes and modulating signaling nodes that shape apoptosis, immune recognition, and transcriptional regulation. Aberrant MAGEA3 expression is associated with malignant progression and tumor immunobiology, making it a useful molecular handle for dissecting antigen expression control and oncogenic rewiring. In cell models, MAGE-A3 is commonly studied in contexts involving epigenetic regulation of cancer-testis genes and pathways that govern survival under proteotoxic and metabolic stress.
MAGE-A3 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the MAGEA3 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within MAGEA3. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt MAGEA3 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of MAGEA3-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.